Allergic diseases are among the most common in the world, covering up to 20% of the population. This is facilitated by environmental problems with an increasing number of different allergens and immune disorders with the accumulation of specific autoantibodies and cytokines. Unfortunately, the generally accepted therapeutic measures for these various manifestations of allergies are mainly symptomatic for the removal of specific symptoms. All this determines the difficulties in treatment with the transition to chronic forms of disease, and in some cases accompanied by a fatal outcome. Truly pathogenetic treatment is apheresis therapy aimed at removing allergens, tissue degradation products, inflammatory mediators, leukotrienes, autoantibodies and immune complexes from the body.